Predictive Oncology Launches Website Highlighting Advances In Cancer Research Powered By AI | Your money


MINNEAPOLIS, Oct 19, 2021 (GLOBE NEWSWIRE) – Predictive Oncology, an oncology and cancer research company using big data and machine learning to improve pharmaceutical development and predictive treatment outcomes, today launched a website that emphasizes its role in advancing its mission.

The website contains information about Predictive Oncology and its affiliates, Helomics, Soluble Biotech, and TumorGenesis, all of which are integral to the overall goal of eliminating cancer by predicting treatment outcomes and aiding development and optimization of anticancer drugs.

“The website redesign is really meant to showcase the great work that all of these teams have done and to highlight that they are all contributing to the same big mission under the banner of predictive oncology,” said J. Melville Engle, CEO and Chairman of the Predictive Oncology Council. “Ending cancer is teamwork. We need the analytical capabilities of Helomics and TumorGenesis to accelerate the development of new cancer treatments and we need the expertise of Soluble Biotech to optimize these treatments. Each is essential to our end goal of equipping healthcare providers with what they need to fight cancer and win. “

Here’s a look at each of Predictive Oncology’s subsidiaries and how they are helping advance cancer research and saving lives:



maintains a database that includes information on 137 tumor types and over 15 years of treatment outcome data covering over 150,000 clinical cases. Helomics relies on proprietary artificial intelligence software, known as the Computational Research Engine (CoRE â„¢), to analyze this rich data set and customize cancer therapies for patients. It can also help spur the development of new, targeted therapies in collaboration with pharmaceutical companies, find effective treatments faster, and help them move to clinical trials. Soluble biotechnology:

Soluble biotechnology

is a supplier of soluble and stable formulations for proteins, including vaccines, antibodies, large and small proteins and protein complexes. Soluble Biotech can help reduce the cost, time and resource demand conventionally required to optimize formulations, reducing the average time from one year to just three months. Genesis of the tumor:

Tumor Genesis

allows researchers to better study cancer cells found in tumors of the blood and all organ systems. TumorGenesis achieves this by growing cancer cells in the lab while retaining the unique DNA / RNA and proteomic signatures that would exist inside a patient’s body. In this way, TumorGenesis provides a granular view of the tumor and the information needed to effectively treat the patient’s cancer. Currently, TumorGenesis is focused on the study of cancerous ovarian tumors, covering 25 ovarian cancer cell lines accounting for 90% of ovarian cancers.

“Eliminating cancer may seem like an ambitious goal, and indeed, such a complex disease will not be cured overnight,” said Engle. “But, with modern technology and the power of artificial intelligence, we have at our disposal some of the most powerful tools to solve the challenges we face in cancer research. Now that we can contextualize and intersect hundreds of thousands of case studies with detailed information about each tumor we have received, we can ensure that our treatments are tailor-made to be most effective for each patient.

About predictive oncology

Predictive Oncology Inc. (NASDAQ: POAI) is a knowledge-driven company focused on the application of artificial intelligence (AI) to develop personalized cancer therapies, which can lead to more effective treatments and better patient outcomes. Using artificial intelligence, Predictive Oncology uses a database of more than 150,000 cancerous tumors, categorized by patient type, against drug compounds to determine the optimal therapies to use to ultimately eliminate cancer.

As the drug discovery community realizes, a genomics-based approach to cancer research and drug development is insufficient to realize the promise of personalized therapy. Rather, predictive oncology takes a multiomic approach, which takes into account the vast multitude of factors that make each cancer unique. Rather than operating on the basis of the equivalent of a bird’s eye view, predictive oncology enables a more personalized and effective approach to cancer research and treatment.

Forward-looking statements

Certain matters discussed in this press release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections regarding future events and are subject to substantial risks, uncertainties and assumptions regarding our operations and the investments we make. All statements, other than statements of historical fact, included in this press release regarding our strategy, future operations, future financial condition, future revenues and financial performance, projected costs, prospects, plans and Management’s objectives are forward-looking statements. The words “anticipate”, “believe”, “estimate”, “foresee”, “intend”, “can”, “plan”, “would”, “target” and other similar expressions are intended to identify the statements. forward-looking, although not all forward-looking statements contain these identifying words. Our actual future performance may differ materially from that contemplated in forward-looking statements due to various factors, including, but not limited to, the factors discussed under “Risk Factors” in our filings with the SEC. Unless expressly required by law, the Company disclaims any intention or obligation to update these forward-looking statements.

Investor Relations Contact:

Landon Capital Keith Pinder (404) 995-6671 [email protected] Media contact: [email protected]

Copyright 2021 GlobeNewswire, Inc.

Leave A Reply

Your email address will not be published.